Trials / Completed
CompletedNCT02447978
Duration of Protection: GSK DTaP Vaccines
Duration of Protection Following Five Doses of GlaxoSmithKline's (GSK's) DTaP Vaccines in School Age Children
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 47 Months – 15 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess duration of protection for GSK DTaP vaccines in preventing pertussis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infanrix | Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age. |
| BIOLOGICAL | Pediarix | Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday). |
| BIOLOGICAL | Kinrix | Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2015-05-19
- Last updated
- 2015-11-02
Source: ClinicalTrials.gov record NCT02447978. Inclusion in this directory is not an endorsement.